Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2020 5
2021 5
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.
Cohen S, Akmaev VR, Withers JB, Connolly-Strong E. Cohen S, et al. Among authors: connolly strong e. Rheumatol Ther. 2022 Feb;9(1):309-311. doi: 10.1007/s40744-021-00387-9. Epub 2021 Nov 10. Rheumatol Ther. 2022. PMID: 34757533 Free PMC article. No abstract available.
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis.
Strand V, Cohen SB, Curtis JR, Zhang L, Kivitz AJ, Levin RW, Mathis A, Connolly-Strong E, Withers JB. Strand V, et al. Among authors: connolly strong e. Expert Rev Mol Diagn. 2022 Jan;22(1):101-109. doi: 10.1080/14737159.2022.2020648. Epub 2021 Dec 30. Expert Rev Mol Diagn. 2022. PMID: 34937469
Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis.
Strand V, Zhang L, Arnaud A, Connolly-Strong E, Asgarian S, Withers JB. Strand V, et al. Among authors: connolly strong e. Expert Opin Biol Ther. 2022 Jun;22(6):801-807. doi: 10.1080/14712598.2022.2066972. Epub 2022 Apr 23. Expert Opin Biol Ther. 2022. PMID: 35442122
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research.
Tse K, Sangodkar S, Bloch L, Arntsen K, Bae SC, Bruce IN, Connolly-Strong E, Costenbader KH, Dickerson B, Dörner T, Evans S, Kalunian K, Kao AH, Manzi S, Morand EF, Raymond SC, Rovin BH, Schanberg LE, Von Feldt JM, Werth VP, Williams Derricott A, Zook D, Franson T, Getz K, Peña Y, Hanrahan LM; ALPHA Project Global Advisory Committee. Tse K, et al. Among authors: connolly strong e. Lupus Sci Med. 2021 Feb;8(1):e000433. doi: 10.1136/lupus-2020-000433. Lupus Sci Med. 2021. PMID: 33563729 Free PMC article.
Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
Askanase AD, Zhao E, Zhu J, Connolly-Strong E, Furie RA. Askanase AD, et al. Among authors: connolly strong e. Lupus Sci Med. 2020 Apr 21;7(1):e000383. doi: 10.1136/lupus-2020-000383. eCollection 2020. Lupus Sci Med. 2020. PMID: 32399253 Free PMC article. Clinical Trial.
13 results